Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.

MLA

Hitomi Nagayama. “Results of a Phase I Clinical Study Using Autologous Tumour Lysate-Pulsed Monocyte-Derived Mature Dendritic Cell Vaccinations for Stage IV Malignant Melanoma Patients Combined with Low Dose Interleukin-2.” Melanoma Research, vol. 13, no. 5, Oct. 2003, p. 521. EBSCOhost, https://doi.org/10.1097/00008390-200310000-00011.

APA

Hitomi Nagayama. (2003). Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Research, 13(5), 521. https://doi.org/10.1097/00008390-200310000-00011

Chicago

Hitomi Nagayama. 2003. “Results of a Phase I Clinical Study Using Autologous Tumour Lysate-Pulsed Monocyte-Derived Mature Dendritic Cell Vaccinations for Stage IV Malignant Melanoma Patients Combined with Low Dose Interleukin-2.” Melanoma Research 13 (5): 521. doi:10.1097/00008390-200310000-00011.